AnaptysBio reports Q2 EPS ($1.71), consensus (89c)

Reports Q2 revenue $10.97M, consensus $24.3M. Cash, cash equivalents and investments totaled $393.5M as of June 30, 2024, compared to $417.9M as of December 31, 2023, for a decrease of $24.4M due primarily to cash used for operating activities offset by $50.0M received from the Sagard royalty monetization completed in May. “We’ve had an exceptional quarter as we approach multiple important value drivers for Anaptys including our first patient data for ANB032, our BTLA agonist. First, enrollment has completed in the Phase 2b trial of ANB032 in AD with strong demand leading to enrollment totaling approximately 200 patients. Importantly, we plan to share top-line Week 14 data in December of 2024,” said Daniel Faga, CEO of Anaptys. “Second, strong demand in enrollment for the Phase 2b trial of rosnilimab in RA has accelerated anticipated top-line data from mid-2025 to Q1 2025. And finally, our IND for ANB033 was accepted by FDA in July and we look forward to initiating a Phase 1 trial in healthy volunteers soon. Looking to the end of the year, we still plan to have four immune cell modulators (ICMs) in clinical development.”